GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are FDA-approved for diabetes and weight loss, but growing evidence suggests their effects may extend beyond blood sugar and body fat, according to a March 27 analysis by The Washington Post.
Researchers have identified 13 areas where GLP-1 drugs show proven, promising or theoretical benefits — including kidney and liver disease, cardiovascular health, sleep apnea, arthritis, substance use and even Alzheimer’s disease. Most benefits are supported by early-stage data, but others, such as heart and kidney protection, are backed by large clinical trials.
Here’s the full list of potential health benefits:
- Kidney disease: A large clinical trial found semaglutide significantly reduced kidney complications in patients with Type 2 diabetes and chronic kidney disease.
- Heart disease: FDA-approved to reduce cardiovascular events in patients with obesity; shown to lower risk of heart attack and stroke.
- Liver disease: Semaglutide improved outcomes for metabolic dysfunction-associated steatohepatitis and liver fibrosis.
- Sleep apnea: Tirzepatide reduced nighttime breathing interruptions in trials; Zepbound approved for moderate to severe cases.
- Alzheimer’s and dementia: Observational studies show reduced risk, but randomized trials have not confirmed cognitive benefit.
- Addiction: Linked to reduced risk of alcohol, nicotine, cannabis and opioid use disorders in veterans; active trials are underway.
- Arthritis and inflammation: Small studies suggest reduced knee pain and systemic inflammation, though weight loss may be a factor.
- Asthma: A U.K. study found symptom improvement in obese patients with asthma, likely due to reduced inflammation.
- Cancers: Early data shows possible protective effects against obesity-related cancers, though risks (e.g., thyroid) are still being studied.
- COVID-19: Semaglutide use associated with fewer complications and lower mortality after infection in people with obesity.
- Fertility: Some evidence suggests GLP-1s may indirectly support fertility through weight loss; research is ongoing.
- “Food noise:” Clinical trials show reduced cravings and obsessive thoughts about food, likely due to brain reward pathway changes.
- Polycystic ovary syndrome: GLP-1s may regulate menstrual cycles and support weight loss in women with PCOS; multiple trials are in progress.
The range of potential benefits is prompting researchers to reexamine how metabolic, immune and neurological systems are connected — and whether a single class of drugs could address multiple chronic conditions at once.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
